ASCO 2013: Dr. Jeff Sharman on Mantle Cell Lymphoma (MCL) and Coffee and Road Map.
Dr. Sharman is a great educator with a super blog on CLL and NHL (Non-Hodgkin's Lymphoma) talks about MCL.
He points out the specific challenges with MCL and why the changes coming to treatment for other B cell lymphomas such as CLL might be even more helpful in this particular nasty cancer.
While not speaking specifically on CLL, the drugs he discusses should be familiar and his explanations of mechanism of action are both clear and creative- like coffee and road maps.
I will be interviewing Dr. Sharman and many others at iwCLL, a CLL specific conference in Cologne, Germany in a few weeks, so stay tuned. Please let me know if you have any burning questions.
Here is the short ASCO interview:
Again my thanks to the team at Patient Power with whom I worked at ASCO. Andrew Schorr and his team do important work for the CLL and cancer community, and it has been a pleasure to pool our energies and resources.
He points out the specific challenges with MCL and why the changes coming to treatment for other B cell lymphomas such as CLL might be even more helpful in this particular nasty cancer.
While not speaking specifically on CLL, the drugs he discusses should be familiar and his explanations of mechanism of action are both clear and creative- like coffee and road maps.
I will be interviewing Dr. Sharman and many others at iwCLL, a CLL specific conference in Cologne, Germany in a few weeks, so stay tuned. Please let me know if you have any burning questions.
Here is the short ASCO interview:
Again my thanks to the team at Patient Power with whom I worked at ASCO. Andrew Schorr and his team do important work for the CLL and cancer community, and it has been a pleasure to pool our energies and resources.
Labels: ASCO 2013, Dr. Sharman, ibrutinib, Lenalidomide, MCL. Mantle Cell Lymphoma, Rituximab, Video
posted by Brian Koffman at
3:47 PM
2 Comments:
Brian,
Thanks for all the interviews. My burning question is will frontline treatment, away from chemo, be an option anytime in the next year or so? It seems that clinical trials for treatment naive are just starting and doubtful that we can avoid FCR, BR etc. Do any of the CLL specialists see any alternatives to FCR in the short run?
Thanks, Heléne
Thanks Brian,
Very interesting as a start point to think about all new options Dr. Sharman mentioned. It will be good to have some current "stastic" interview to compare all three options Dr. Sharman mentioned that includes Ibrutinib and BMT. I mean response rate, time of remission vs. time of treatment and mortality rate.
All the best,
Mike
Post a Comment
Subscribe to Post Comments [Atom]
<< Home